

IMMUCELL CORP /DE/  
Form 8-K  
July 25, 2017

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report: July 24, 2017**  
(Date of earliest event reported)

**ImmuCell Corporation**  
(Exact name of registrant as specified in its charter)

|  |  |  |
|--|--|--|
| <b>DE</b><br>(State or other jurisdiction<br>of incorporation) | <b>001-12934</b><br>(Commission File Number) | <b>01-0382980</b><br>(IRS Employer<br>Identification Number) |
|--|--|--|

**56 Evergreen Drive**  
**04103**  
**Portland, Maine**  
(Address of principal executive offices) (Zip Code)

**207-878-2770**  
(Registrant's telephone number, including area code)

**Not Applicable**

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.01 – Entry into a Material Definitive Agreement**

On July 24, 2017, ImmuCell entered into an amendment to its agreement with Plas-Pak Industries Inc. of Norwich, Connecticut, originally dated as of January 4, 2010 and previously amended as of October 14, 2015, covering the supply of plastic syringes for use in ImmuCell’s Nisin-based product under development for the treatment of subclinical mastitis in lactating dairy cows. The current amendment extends the expiration date of the agreement by three years to January 1, 2024.

The information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 25, 2017 **IMMUCELL CORPORATION**

By: /s/ Michael F Brigham  
Michael F. Brigham  
*President, Chief Executive Officer  
and Principal Financial Officer*